LEFLUNOMIDE tablet

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv ingrediens:

LEFLUNOMIDE (UNII: G162GK9U4W) (LEFLUNOMIDE - UNII:G162GK9U4W)

Tilgjengelig fra:

Alembic Pharmaceuticals Inc.

INN (International Name):

LEFLUNOMIDE

Sammensetning:

LEFLUNOMIDE 10 mg

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

Leflunomide tablets USP are indicated for the treatment of adults with active rheumatoid arthritis (RA).  Leflunomide is contraindicated in: ·            Pregnant women. Leflunomide may cause fetal harm. If a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see Warnings and Precautions (5.1 and 5.3) and Use in Specific Populations (8.1)].   ·            Patients with severe hepatic impairment [see Warnings and Precautions (5.2)]. ·            Patients with known hypersensitivity to leflunomide or any of the other components of leflunomide. Known reactions include anaphylaxis [see Adverse Reactions (6.1)]. ·             Patients being treated with teriflunomide [see Drug Interactions (7)]. Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. Health care providers and patients are encouraged to report pr

Produkt oppsummering:

How Supplied Leflunomide tablets USP, 10 mg are white to off white, circular, biconvex, film coated tablets debossed with ‘L115’ on one side and plain on the other side, and are supplied as follows: NDC 62332-061-30                 bottles of 30 tablets NDC 62332-061-60                 bottles of 60 tablets NDC 62332-061-31                 bottles of 100 tablets NDC 62332-061-71                 bottles of 500 tablets Leflunomide tablets USP, 20 mg are yellow colored, triangular, biconvex, film coated tablets debossed with ‘L116’ on one side and plain on the other side, and are supplied as follows: NDC 62332-062-30                 bottles of 30 tablets NDC 62332-062-60                 bottles of 60 tablets NDC 62332-062-31                 bottles of 100 tablets NDC 62332-062-71                 bottles of 500 tablets Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [see USP Controlled Room Temperature]. Protect from light.

Autorisasjon status:

Abbreviated New Drug Application

Preparatomtale

LEFLUNOMIDE - LEFLUNOMIDE TABLET
ALEMBIC PHARMACEUTICALS INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LEFLUNOMIDE TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
LEFLUNOMIDE TABLETS.
LEFLUNOMIDE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
WARNING: EMBRYO-FETAL TOXICITY AND HEPATOTOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
EMBRYO-FETAL TOXICITY
· TERATOGENICITY AND EMBRYO-LETHALITY OCCURRED IN ANIMALS
ADMINISTERED
LEFLUNOMIDE. (5.1, 8.1)
· EXCLUDE PREGNANCY PRIOR TO INITIATING LEFLUNOMIDE THERAPY. (5.1,
8.3)
· ADVISE USE OF EFFECTIVE CONTRACEPTION IN FEMALES OF REPRODUCTIVE
POTENTIAL DURING
TREATMENT AND DURING A DRUG ELIMINATION PROCEDURE. (5.1, 5.3, 8.3)
· STOP LEFLUNOMIDE AND USE AN ACCELERATED DRUG ELIMINATION PROCEDURE
IF THE
PATIENT BECOMES PREGNANT. (5.1, 5.3, 8.1)
HEPATOTOXICITY
· SEVERE LIVER INJURY AND FATAL LIVER FAILURE HAVE BEEN REPORTED.
(5.2)
· AVOID LEFLUNOMIDE USE IN PATIENTS WITH PRE-EXISTING LIVER DISEASE,
OR THOSE WITH
SERUM ALANINE AMINOTRANSFERASE (ALT) >2XULN. (5.2, 8.6)
· USE CAUTION WHEN LEFLUNOMIDE IS GIVEN WITH OTHER POTENTIALLY
HEPATOTOXIC DRUGS.
(5.2)
MONITOR ALT LEVELS. INTERRUPT LEFLUNOMIDE TREATMENT IF ALT ELEVATION >
3 FOLD ULN. IF
LIKELY LEFLUNOMIDE-INDUCED, START ACCELERATED DRUG ELIMINATION
PROCEDURE AND MONITOR
LIVER TESTS WEEKLY UNTIL NORMALIZED. (5.2, 5.3)
INDICATIONS AND USAGE
Leflunomide is a pyrimidine synthesis inhibitor indicated for the
treatment of adults with active rheumatoid
arthritis. (1) (1)
DOSAGE AND ADMINISTRATION
· Loading dosage for patients at low risk for leflunomide-associated
hepatotoxicity and leflunomide-
associated myelosuppression: 100 mg daily for 3 days. (2.1) (2)
· Maintenance dosage: 20 mg daily. (2.1) (2)
Maximum recommended daily dosage: 20 mg once daily. (2.1) (2)
If 20 mg once daily is not tolerated, may decrease dosage to 10 mg
once daily. (2.1) (2)
· Screen patients for active and latent tuberculosis, pr